|
ADVR Granted U.S. Patent for Treatment of Human Papillomavirus
Infections Dec 11, 2003 ADVR Names Elma S. Hawkins to Board of Directors Dec 9, 2003 AVR118 Suppresses Progression of Disease in Animal Model of Multiple Sclerosis Developed at The Weizmann Institute of Science Dec 3, 2003 ADVR Reports AVR118 Inhibits Inflammatory Arthritis in Animal Model and in Rheumatoid Arthritis Patients in Human Clinical Trial Nov 20, 2003 ADVR's AVR118 Granted a Patent in China for the Treatment of AIDS Nov 18, 2003 Advanced Viral Research Corp. Announces Retention of James T. D'Olimpio, MD As 'Spokesperson at Large' Nov 10, 2003 ADVR Reports Positive Preliminary Results of AVR118 Clinical Trial in AIDS Patients Suffering from Body Wasting (Cachexia) Aug 28, 2003 ADVR Announces Search for New CEO and Appointment of Interim CEO May 16, 2003 ADVR Completes Private Placement Financing Transactions Apr 11, 2003 ADVR CEO Hirschman Comments on SARS on ABC World News Tonight Mar 24, 2003 ADVR Granted Therapeutic Composition Patent For Product R; U.S. Patent Awarded for Chemical Structure of Novel Peptide Nucleic Acid Mar 18, 2003 ADVR Begins Planning for Late Stage Phase II AIDS Clinical Trial In Israel Feb 25, 2003 ADVR Pursuing Options in NY Litigation; Continues to Press Florida Lawsuit Jan 9, 2003 ADVR Completes Private Placement Financing Transaction Dec 17, 2002 ADVR Files Stock Manipulation Suit in Florida Dec 12, 2002 Potential Use of ADVR's Product R to Treat AIDS Is Focus of A&U Magazine Article Nov 14, 2002 ADVR Begins Product R Israeli Clinical Trials; Quintiles Retained to Monitor/Audit Trials, Selikoff Center to Conduct Trials Nov 8, 2002 ADVR Announces Staff Reduction to Conserve Capital to Focus on Israeli Clinical Trials; Intent to Sell Bahamas Plant; Board Resignations Oct 11, 2002 ADVR's Product R Reverses Cancerous Properties of Human Promyelocytic Leukemia Cells in Laboratory Cultures Sep 25, 2002 Dr. Richard S. Kent Joins ADVR Board of Directors Sep 18, 2002 Dr. Sidney Pestka Joins ADVR Scientific Advisory Board Sep 10, 2002 ADVR Announces Completion of $3 Million Financing; Funds Enable Israeli Clinical Trials of Product R to Move Forward Aug 20, 2002 ADVR's Product R Subject of Published Study on Clinical Trial For Treatment of HIV/AIDS Jul 30, 2002 Paul R. Bishop Joins ADVR Board of Directors Jul 16, 2002 ADVR Announces $1.5 Million Investment By Member of Board and Member of Business Advisory Board Jun 18, 2002 ADVR's Product R Approved in Israel for Phase I Study In Patients with Solid Tumors Jun 12, 2002 ADVR's Product R Approved in Israel for Phase I Study in Leukemia and Lymphoma Patients Jun 10, 2002 Roy S. Walzer Joins Board of Directors of Advanced Viral Research Corp. Jun 6, 2002 ADVR's Product R Approved in Israel for Phase I/II Study In Patients Needing Salvage Therapy For AIDS May 23, 2002 ADVR Names Mayr Communications to Handle Public/Investor Relations; Firm Brings Extensive Pharmaceutical Industry Experience May 2, 2002 ADVR Names Eli Wilner Chairman of the Board Apr 23, 2002 ADVR's Dr. Hirschman Describes Large Potential Therapeutic Categories for Product R Apr 16, 2002 ADVR Is Assigned Ownership of Two U.S. Patents in Settlement of Litigation Apr 12, 2002 ADVR Begins Phase 2 of IND for Topical Treatment Of Genital Warts With Product R Mar 20, 2002 ADVR's Product R Granted Patent for Topical Use In Treatment of Skin Diseases, Eye Afflictions Mar 15, 2002 Dr. Howard Young - Leading Immunologist - Joins the Scientific Advisory Board Of Advanced Viral Research Corp. Mar 11, 2002 Advanced Viral Research Corp. Submits Product R Topical Phase 1 Results to FDA Jan 24, 2002 Advanced Viral Research Corp. Forms Scientific Advisory Board with Leaders in Oncology, Hematology, Women's Health Care News Headlines from: |